Brian Kimmel, DO
Family Medicine · Philadelphia, PANPI 1528007176
Payments from drug & device makers
Across 106 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$186
- Acadia Pharmaceuticals Inc$169
- E.r. Squibb & Sons, L.L.C.$161
- AstraZeneca$148
- Sunovion Pharmaceuticals Inc.$117
- Novartis$112
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,170100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $186 |
| Acadia Pharmaceuticals Inc | 2 | $169 |
| E.r. Squibb & Sons, L.L.C. | 4 | $161 |
| AstraZeneca | 8 | $148 |
| Sunovion Pharmaceuticals Inc. | 8 | $117 |
| Novartis | 7 | $112 |
| Teva Pharmaceuticals USA, Inc. | 7 | $108 |
| Pfizer | 5 | $91 |
| Exact Sciences | 3 | $89 |
| Xeris Pharmaceuticals, Inc. | 4 | $88 |
| Mylan Specialty L.p. | 2 | $82 |
| Avanir Pharmaceuticals, Inc. | 4 | $81 |
| UCB, Inc. | 5 | $80 |
| Bayer | 4 | $76 |
| Lilly USA, LLC | 4 | $62 |
| Aimmune Therapeutics, Inc. | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $39 |
| GSK | 2 | $38 |
| Alkermes, Inc. | 2 | $36 |
| Dexcom, Inc. | 1 | $33 |
| Lundbeck LLC | 1 | $33 |
| AbbVie | 2 | $28 |
| Merck | 2 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Novo Nordisk | 1 | $22 |
| SK Life Science, Inc. | 1 | $20 |
| Viiv Healthcare Company | 1 | $18 |
| Biogen | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Amgen | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Urovant Sciences Inc | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,170 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,795 | $571,262 |
| XifaxanRifaximin | 107 | $157,463 |
| XareltoRivaroxaban | 317 | $114,855 |
| FarxigaDapagliflozin Propanediol | 212 | $94,197 |
| JanuviaSitagliptin Phosphate | 193 | $86,189 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 19 | $75,447 |
| TradjentaLinagliptin | 208 | $56,155 |
| Breo ElliptaFluticasone/Vilanterol | 158 | $54,701 |
| EntrestoSacubitril/Valsartan | 153 | $52,990 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $52,624 |
| TrulicityDulaglutide | 96 | $50,721 |
| JardianceEmpagliflozin | 107 | $49,952 |
| Atorvastatin Calcium | 2,737 | $44,259 |
| MyrbetriqMirabegron | 167 | $42,681 |
| VascepaIcosapent Ethyl | 84 | $30,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $91 | $571,2621,795 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $12 | $157,463107 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $38 | $153,908388 claims |
| Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat, Spiriva Respimat | $18 | $141,689378 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $148 | $121,249251 claims |
| Johnson & JohnsonXarelto | $18 | $114,855317 claims |
| MerckJanuvia | $27 | $86,189193 claims |
| NovartisEntresto | $112 | $52,990153 claims |
| Lilly USA, LLCTrulicity | $62 | $50,72196 claims |
| AbbVieLinzess, Vraylar | $28 | $42,83760 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $42,681167 claims |
| Viiv Healthcare CompanyTivicay | $18 | $30,66515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Daniel LinPhiladelphia$392K
- Glenn RosenPhiladelphia$367K
- Christopher ChambersPhiladelphia$350K
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.